Financial Review: Oruka Therapeutics (ORKA) and Its Competitors

Oruka Therapeutics (NASDAQ:ORKA) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it compare to its peers? We will compare Oruka Therapeutics to related businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Profitability

This table compares Oruka Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
Oruka Therapeutics Competitors	-1,887.40%	-40.50%	-25.93%

Risk and Volatility

Oruka Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ peers have a beta of 1.33, meaning that their average stock price is 33% more volatile than the S&P 500.

Institutional & Insider Ownership

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are held by institutional investors. 30.9% of Oruka Therapeutics shares are held by company insiders. Comparatively, 13.2% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Oruka Therapeutics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oruka Therapeutics	N/A	-$5.34 million	-4.34
Oruka Therapeutics Competitors	$551.28 million	$6.13 million	-116.32

Oruka Therapeutics’ peers have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings for Oruka Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	6	2	3.25
Oruka Therapeutics Competitors	846	798	1347	23	2.18

Oruka Therapeutics presently has a consensus price target of $43.17, indicating a potential upside of 65.77%. As a group, “Diagnostic substances” companies have a potential upside of 32.28%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than its peers.

Summary

Oruka Therapeutics beats its peers on 10 of the 13 factors compared.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.